BiO2 Medical Inc. Prophylactic Pulmonary Embolism Protection Hospitalized patients are at the greatest risk for a fatal pulmonary embolism within the first 10 days after admission, but traditional inferior vena cava filters to prevent PEs if anticoagulant therapy is contraindicated and/or ineffective are not typically placed in ...
BiO2 Medical Sponsors: Journal of the Intensive Care Society Supplement Pulmonary Embolism – The Future – Optimizing the Prevention of PE in the Critically Ill Patient
Pulmonary embolism – the future Optimising the prevention of PE in the critically ill patient Venous thromboembolism (VTE) remains a major challenge in the care of critically ill patients. Patients in the intensive care unit (ICU) are at high risk for both deep vein thrombosis (DVT) and pulmonary embolism (PE). PE frequently occurs ...
BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter
BiO2 Medical, Inc. is proud to announce the Angel® Catheter Early Feasibility Clinical Study has enrolled its first 3 subjects. Research teams led by Dr. John Holcomb at University of Texas, Houston(Memorial Hermann Hospital) and Dr. Larry Martin at University of Mississippi, Jackson participated in these cases with the first ...
BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter
BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has signed a distribution agreement with Pyramed, a division of United Drug Medical (UDM). This milestone accomplishment grants Pyramed exclusive rights to distribute the Angel® Catheter throughout ...